secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001193125-25-132301
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics appoints Matthew Abernethy to board; shareholders boost authorized shares to 350M
--------------------------------------------------------------------------------

- Matthew Abernethy, CFO of Neurocrine Biosciences, appointed Class III director; Timothy P. Coughlin steps down.
- Stockholders approved increase in authorized common shares from 250M to 350M, effective May 29, 2025.
- Second amendment to 2022 stock plan approved, adding 7M shares to the reserve.
- Dr. Shefali Agarwal and Dr. Bahram Valamehr re-elected Class III directors; E&Y ratified as auditor.
- Non-binding say-on-pay passed with ~68.9M for (92.4% of votes cast); frequency set at 1 year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/0001193125-25-132301-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000119312525132301/d42374d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132301

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer